ADAMS STREET PARTNERS, LLC
This is a pooled fund: many plans invest in it, and it holds the underlying securities.
This filing is a Direct Filing Entity (DFE) — a master trust or collective investment trust that pools assets from multiple participating plans. It does not have plan participants of its own, and the Plan Health Score formula doesn’t apply. Individual participant-facing plans that invest in this trust are the appropriate target for fiduciary analysis.
Cited interest vs pooled assets: cited interest sums what each participating plan reported holding in this trust, measured at that plan’s own year-end — and those filings span different years. Pooled assets is this single filing’s balance at one date. They’re independent measurements, so cited interest can land slightly above or below the pooled balance and won’t reconcile exactly.
Why no Schedule of Assets here? DFE holdings often live on the master trust’s own audited statement, not as a 4i schedule on the participating plans’ filings. We’re extending the parsing pipeline to cover DFE filings — see Methodology.
Service providers (Schedule C)
4 rows| Name | EIN | Location | Relation | Direct comp | Indirect comp |
|---|---|---|---|---|---|
| ADAMS STREET PARTNERS LP | 36-4395128 | — | NONE | $635K | — |
| KPMG LLP | 13-5565207 | — | NONE | $86K | — |
| T. ROWE PRICE ASSOCIATES, INC. | 52-0556948 | — | NONE | $13K | — |
| JP MORGAN CHASE BANK | 13-4994650 | — | NONE | $7K | — |
Investments
| PI | Investment | Type | Shares / units | Cost | Current value | % of plan |
|---|---|---|---|---|---|---|
| Index Ventures VI | — | — | $3.7M | $19.4M | 16.2% | |
| Pitango Venture Capital Fund VI | — | — | $2.6M | $12.3M | 10.3% | |
| Accel London IV | — | — | $3.4M | $10.4M | 8.6% | |
| Palamon European Equity III 'A' | — | — | $8.1M | $8.0M | 6.7% | |
| JPMorgan US Government Money Market Fund | — | — | $6.8M | $6.8M | 5.6% | |
| TDR Capital III | — | — | $3.2M | $6.4M | 5.4% | |
| Affinity Asia Pacific Fund IV | — | — | $6.3M | $6.4M | 5.3% | |
| Aleph | — | — | $3.2M | $5.6M | 4.7% | |
| HitecVision VII | — | — | $8.7M | $4.9M | 4.1% | |
| Oakley Capital Private Equity II-B | — | — | $5.5M | $4.2M | 3.5% | |
| Medicxi Secondary I | — | — | $2.1M | $4.0M | 3.4% | |
| Prime Ventures IV | — | — | $3.4M | $3.2M | 2.7% | |
| HitecVision VI | — | — | $5.1M | $2.8M | 2.4% | |
| BC European Capital IX | — | — | $4.5M | $2.7M | 2.2% | |
| Vitruvian Investment Partnership II-B LP | — | — | $4.1M | $2.4M | 2.0% | |
| Index Ventures Growth Fund II | — | — | $2.4M | $2.3M | 2.0% | |
| Investindustrial V LP | — | — | $4.4M | $2.2M | 1.8% | |
| Nordic Capital VIII Beta | — | — | $4.9M | $1.6M | 1.4% | |
| Palamon European Equity II | — | — | $4.9M | $1.6M | 1.3% | |
| Index Ventures Life VI | — | — | $1.1M | $1.3M | 1.1% | |
| Xilos Co-Investment No. 1 Separate Limited | — | — | $1.1M | $1.2M | 1.0% | |
| Living Bridge 5 | — | — | $1.1M | $1.1M | 1.0% | |
| Polish Enterprise Fund VII | — | — | $2.9M | $911K | 0.8% | |
| Advent International GPE VII-E | — | — | $2.8M | $904K | 0.8% | |
| L Capital 3 | — | — | $730K | $855K | 0.7% | |
| Alchemy Special Opportunities Fund II | — | — | $1.2M | $846K | 0.7% | |
| TDR Capital II | — | — | $2.4M | $844K | 0.7% | |
| DBAG Fund VI | — | — | $2.0M | $669K | 0.6% | |
| Item 4i - Schedule of Assets (Held At End of Year) Subheader Investments Cost Fair Value Abingworth Bioventures VI | — | — | $1.2M | $629K | 0.5% | |
| Quadrant Private Equity III | — | — | $1.4M | $483K | 0.4% | |
| Crescent Capital Partners IV | — | — | $2.6M | $352K | 0.3% | |
| Quadrant Private Equity No.4 | — | — | $5K | $344K | 0.3% | |
| Piper Private Equity Fund V | — | — | $668K | $303K | 0.3% | |
| Advent International Global Private Equity VI-C | — | — | $1.4M | $246K | 0.2% | |
| Latour Capital I | — | — | $326K | $242K | 0.2% | |
| CVC European Equity Partners V | — | — | $2.3M | $239K | 0.2% | |
| Waterland Private Equity Fund V C.V. | — | — | $38K | $177K | 0.1% | |
| France Special Situations Fund I | — | — | $9.0M | $163K | 0.1% | |
| Atlantic and Pacific VI | — | — | $213K | $129K | 0.1% | |
| Archer Capital 5 | — | — | $1.3M | $116K | <0.1% | |
| New Enterprise Associates 12 | — | — | $3.1M | $111K | <0.1% | |
| Affinity Asia Pacific Fund III | — | — | $1.4M | $109K | <0.1% | |
| Charterhouse Capital Partners IX | — | — | $2.4M | $40K | <0.1% | |
| Vitruvian Investment Partnership I | — | — | $144K | $19K | <0.1% | |
| Astorg V | — | — | $1.8M | $18K | <0.1% | |
| HitecVision V | — | — | $4.6M | $14K | <0.1% | |
| HitecVision Assets Solutions | — | — | $950K | $6K | <0.1% | |
| HitecVision SpringPoint LP 0 | — | — | — | $6K | <0.1% | |
| Warburg Pincus Private Equity IX | — | — | $241K | $3K | <0.1% | |
| G Square Capital I | — | — | $3.4M | $2K | <0.1% | |
| HitecVision SpringPoint LP 0 | — | — | — | $1K | <0.1% |